BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 10942236)

  • 1. Inhibition of RNA transcription: a biochemical mechanism of action against chronic lymphocytic leukemia cells by fludarabine.
    Huang P; Sandoval A; Van Den Neste E; Keating MJ; Plunkett W
    Leukemia; 2000 Aug; 14(8):1405-13. PubMed ID: 10942236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fludarabine-mediated suppression of the excision repair enzyme ERCC1 contributes to the cytotoxic synergy with the DNA minor groove crosslinking agent SJG-136 (NSC 694501) in chronic lymphocytic leukaemia cells.
    Pepper C; Lowe H; Fegan C; Thurieau C; Thurston DE; Hartley JA; Delavault P
    Br J Cancer; 2007 Jul; 97(2):253-9. PubMed ID: 17579621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fludarabine increases oxaliplatin cytotoxicity in normal and chronic lymphocytic leukemia lymphocytes by suppressing interstrand DNA crosslink removal.
    Moufarij MA; Sampath D; Keating MJ; Plunkett W
    Blood; 2006 Dec; 108(13):4187-93. PubMed ID: 16954499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Hsp90 inhibitor SNX-7081 is synergistic with fludarabine nucleoside via DNA damage and repair mechanisms in human, p53-negative chronic lymphocytic leukemia.
    Kaufman KL; Jenkins Y; Alomari M; Mirzaei M; Best OG; Pascovici D; Mactier S; Mulligan SP; Haynes PA; Christopherson RI
    Oncotarget; 2015 Dec; 6(38):40981-97. PubMed ID: 26556860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Killing of chronic lymphocytic leukemia by the combination of fludarabine and oxaliplatin is dependent on the activity of XPF endonuclease.
    Zecevic A; Sampath D; Ewald B; Chen R; Wierda W; Plunkett W
    Clin Cancer Res; 2011 Jul; 17(14):4731-41. PubMed ID: 21632856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Equilibrative nucleoside transporter-2 (hENT2) protein expression correlates with ex vivo sensitivity to fludarabine in chronic lymphocytic leukemia (CLL) cells.
    Molina-Arcas M; Marcé S; Villamor N; Huber-Ruano I; Casado FJ; Bellosillo B; Montserrat E; Gil J; Colomer D; Pastor-Anglada M
    Leukemia; 2005 Jan; 19(1):64-8. PubMed ID: 15510196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Basic fibroblast growth factor (bFGF) upregulates the expression of bcl-2 in B cell chronic lymphocytic leukemia cell lines resulting in delaying apoptosis.
    König A; Menzel T; Lynen S; Wrazel L; Rosén A; Al-Katib A; Raveche E; Gabrilove JL
    Leukemia; 1997 Feb; 11(2):258-65. PubMed ID: 9009090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Hsp90 inhibitor SNX-7081 synergizes with and restores sensitivity to fludarabine in chronic lymphocytic leukemia cells with lesions in the TP53 pathway: a potential treatment strategy for fludarabine refractory disease.
    Best OG; Che Y; Singh N; Forsyth C; Christopherson RI; Mulligan SP
    Leuk Lymphoma; 2012 Jul; 53(7):1367-75. PubMed ID: 22149137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The novel nuclear factor-kappaB inhibitor LC-1 is equipotent in poor prognostic subsets of chronic lymphocytic leukemia and shows strong synergy with fludarabine.
    Hewamana S; Lin TT; Jenkins C; Burnett AK; Jordan CT; Fegan C; Brennan P; Rowntree C; Pepper C
    Clin Cancer Res; 2008 Dec; 14(24):8102-11. PubMed ID: 19088025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nitric oxide enhancement of fludarabine cytotoxicity for B-CLL lymphocytes.
    Adams DJ; Levesque MC; Weinberg JB; Smith KL; Flowers JL; Moore J; Colvin OM; Silber R
    Leukemia; 2001 Dec; 15(12):1852-9. PubMed ID: 11753605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA-PK, ATM and MDR proteins inhibitors in overcoming fludarabine resistance in CLL cells.
    Svirnovski AI; Serhiyenka TF; Kustanovich AM; Khlebko PV; Fedosenko VV; Taras IB; Bakun AV
    Exp Oncol; 2010 Dec; 32(4):258-62. PubMed ID: 21270755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transposon Mutagenesis Reveals Fludarabine Resistance Mechanisms in Chronic Lymphocytic Leukemia.
    Pandzic T; Larsson J; He L; Kundu S; Ban K; Akhtar-Ali M; Hellström AR; Schuh A; Clifford R; Blakemore SJ; Strefford JC; Baumann T; Lopez-Guillermo A; Campo E; Ljungström V; Mansouri L; Rosenquist R; Sjöblom T; Hellström M
    Clin Cancer Res; 2016 Dec; 22(24):6217-6227. PubMed ID: 26957556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Constitutively Photomorphogenic 1 Reduces the Sensitivity of Chronic Lymphocytic Leukemia Cells to Fludarabine Through Promotion of Ubiquitin-Mediated P53 Degradation.
    Fu C; Shi X; Gong Y; Wan Y; Sun Z; Shi H; Wang Z; Marinaccio C; Crispino JD; Xu K
    Cell Physiol Biochem; 2018; 50(6):2314-2328. PubMed ID: 30423551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The MEK1/2 inhibitor, MEKi-1, induces cell death in chronic lymphocytic leukemia cells under conditions that mimic the tumor microenvironment and is synergistic with fludarabine.
    Crassini K; Stevenson WS; Mulligan SP; Best OG
    Leuk Lymphoma; 2015; 56(12):3407-17. PubMed ID: 25804768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of IL-4 level by fludarabine and its relation to apoptosis in chronic B-cell lymphocytic leukemia.
    Shamaa LA; Hussein Ael-S; Balbaa OA; Farahat NM; Ali MA
    Egypt J Immunol; 2008; 15(1):181-92. PubMed ID: 20306682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased mitochondrial biogenesis in primary leukemia cells: the role of endogenous nitric oxide and impact on sensitivity to fludarabine.
    Carew JS; Nawrocki ST; Xu RH; Dunner K; McConkey DJ; Wierda WG; Keating MJ; Huang P
    Leukemia; 2004 Dec; 18(12):1934-40. PubMed ID: 15483672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [SYNERGISTIC ACTIVITY OF DEGUELIN AND FLUDARABINE IN PRIMARY CELLS FROM CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS (CLL) AND IN A CLL MURINE MODEL].
    Vargas Núñez JA
    An R Acad Nac Med (Madr); 2014; 131(2):441-56. PubMed ID: 27400564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Arsenic trioxide synergistically potentiates the cytotoxic effect of fludarabine in chronic lymphocytic leukemia cells by further inactivating the Akt and ERK signaling pathways.
    Lozano-Santos C; Amigo-Jiménez I; Nova-Gurumeta S; Pérez-Sanz N; García-Pardo A; García-Marco JA
    Biochem Biophys Res Commun; 2015 May; 461(2):243-8. PubMed ID: 25869069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fludarabine induces apoptosis in chronic lymphocytic leukemia--the role of P53, Bcl-2, Bax, Mcl-1, and Bag-1 proteins.
    Faria JR; Yamamoto M; Faria RM; Kerbauy J; Oliveira JS
    Braz J Med Biol Res; 2006 Mar; 39(3):327-33. PubMed ID: 16501812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fludarabine-induced apoptosis in CD19+/CD5+B-CLL cells is a direct and nurse-like-cell independent effect.
    Martinez-Lostao L; Briones J; Martinez-Gallo M; Forné I; Sierra J; Rodriguez-Sanchez JL; Juarez C
    Leuk Lymphoma; 2004 Nov; 45(11):2307-14. PubMed ID: 15512822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.